GORE ® VIABAHN ® Device for Arteriovenous Access (Revision) Speaker Slideset GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates.

Slides:



Advertisements
Similar presentations
Drug Coated Balloons From Bench to Bedside Service de Radiodiagnostic et Radiologie Interventionnelle Université de Lausanne Salah D. Qanadli, MD, PhD,
Advertisements

RENOVA: A Multicenter, Randomized, Controlled Clinical Study of an Endovascular Stent Graft vs. PTA: 12-Month Interim Results *On Behalf of the RENOVA.
ACC 2015 Michael J Reardon, MD, FACC On Behalf of the CoreValve US Investigators A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic.
Viabahn Covered Stents for Cephalic Arch Stenosis Can Improve Patency and Longevity of Upper Arm AV Fistulas Toufic Safa, MD, FACS Vascular & Endovascular.
GRAFT Thrombosis: Recent trends in Management
Superficial Femoral Artery Stents - Bare, Covered, or Drug-Coated – “The Data and The HYPE” Dennis F. Bandyk, MD Division of Vascular & Endovascular Surgery.
FAST (Femoral Artery Stenting Trial) Final Results Hans Krankenberg (on behalf of the FAST Investigators) Hamburg University Cardiovascular Center Prof.
GORE, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2009 W. L. Gore & Associates, Inc. 1 GORE VIABAHN ® Endoprosthesis Speaker’s.
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
Evaluation of ReeKross balloon catheter in treating iliofemoral artery chronic total occlusions Xinwu Lu Vascular Center of Shanghai Jiaotong University.
Is There Still a Controversy About Stent Type for TASC C&D Lesions
Findings/Discussion AV fistula with outflow stenosis far from anastomosis Stenosis typically due to fibrotic, hyperplastic or elastic lesions. –Increased.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Natural Suturability & Compliance AV ACCESS ML (06/2015)
Balloon Angioplasty for Low Flow Access
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
TOKUDA HOSPITAL SOFIA VASCULAR SURGERY AND ANGIOLOGY DEPARTMENT DR. A. DASKALOV, ASSOC. PROFF. V. CHERVENKOV.
UpdateDEB Lesions Learned from the Trials and Daily Clinical Practice Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden.
University of Modena and Reggio Emilia Vascular Surgery – Director: prof. Coppi Silingardi R. Veronesi J. Gennai S.
Superficial Femoral Artery – Where Does the Data Stand? Director, Endovascular Services Mehdi H. Shishehbor, DO, MPH, PhD Cleveland Clinic.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Heparin-Bonded Covered Stents Versus Bare-Metal Stents.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Global Experience with Peripheral DCBs/Stent Studies: C.R. Bard
The Endocross Enabler-P: First in-Human Results
Chapter 13 Evaluation of arterial bypass grafts and stents
Can Drug-Coated Balloons Work in Synergy with Stent Grafts?
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Lutonix® Paclitaxel-Coated Balloon to Treat Obstructive Lesions in the Superficial Femoral and Popliteal Arteries Preliminary Six-Month Results from.
Heavily calcified SFA lesions do not avoid the use of 4 F systems
Stent Graft for the Treatment of ISR:
Ten Tips for Dialysis Management
How to do endovascular mechanical thrombaspiration
Eric J Dippel, MD FACC Davenport, Iowa, USA February 19, 2017
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Modern treatment of SFA
The Role of Interventional Treatment for The Failing Grafts
Instent Restenosis and Occlusion: Time for Surgical Revision?
Insights from the IMPERIAL and MAJESTIC SFA Studies
Percutaneous Reconstruction of the Aortoiliac Bifurcation
Precise and Durable Outcomes With the GORE® TIGRIS® Vascular Stent
Are we using fewer Covered Stents for SFA Occlusive Disease?
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Volume 69, Issue 5, Pages (March 2006)
Catheter-Based Treatment of Coronary Artery Disease
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts  Thomas Vesely, MD, William DaVanzo,
Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents  Yiu Che Chan, MBBS, BSc, MD, FRCS, Stephen W.
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
Thermal laser-assisted balloon angioplasty of the superficial femoral artery: A multicenter review of 602 cases  David Rosenthal, MD, Felix A. Pesa, MD,
ILLUMENATE Trial design: Patients with superficial femoral artery (SFA) and/or popliteal arterial stenoses were randomized in a 2:1 fashion to either balloon.
Preliminary clinical outcome and imaging criterion for endovascular prosthesis development in high-risk patients who have aortoiliac and traumatic arterial.
Christopher D. Miller, Michelle L. Robbin, Michael Allon 
Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions  Takao Ohki, MD, PhD, Kimihiko.
Vascular access surveillance: an ongoing controversy
Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts  Thomas Vesely, MD, William DaVanzo,
Percutaneous transluminal angioplasty for the treatment of limb threatening ischemia: Do the results justify an attempt before bypass grafting?  Richard.
Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease  Jean-Baptiste Ricco,
Stenting of the venous outflow in chronic venous disease: Long-term stent-related outcome, clinical, and hemodynamic result  Peter Neglén, MD, PhD, Kathryn.
Use of the Viabahn stent graft for the treatment of recurrent cephalic arch stenosis in hemodialysis accesses  Gregg A. Miller, MD, Dean C. Preddie, MD,
The American College of Cardiology Presented by Dr. A. Abazid
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Vascular access for hemodialysis
Presentation transcript:

GORE ® VIABAHN ® Device for Arteriovenous Access (Revision) Speaker Slideset GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Product Overview Approved in June 2005, the GORE ® VIABAHN ® Endoprosthesis is the only stent-graft available in the US with an SFA, Iliac, and AV Access indication. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. The GORE ® VIABAHN ® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm, in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm, and in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE ® VIABAHN ® Endoprosthesis is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events.

Restenosis can Occur within Minutes or Hours After a Successful Angioplasty Severe stenosis of cephalic vein Good result immediately after balloon angioplasty Restenosis 30 minutes later due to elastic recoil A C B This study is a representative case. Individual results may vary. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Total Endoluminal Bypass: Preventing In-Stent Stenosis The GORE ® VIABAHN ® Endoprosthesis covers and seals off the diseased and irregular tissue of the arterial wall. In contrast, a bare nitinol stent covers only a small portion of the diseased arterial lumen. Individual results may vary. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Diffuse In-stent Stenosis is the Common Failure Mode of Bare Metal Stents These studies are representative cases. Individual results may vary. 1 GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Bare Metal Stent Outcomes Similar to PTA BARD ® and FLAIR ® are trademarks of C. R. Bard, Inc. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Flexibility to Conform with the Anatomy These studies are representative cases. Individual results may vary. BARD ® and FLAIR ® are trademarks of C. R. Bard, Inc. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

These studies are representative cases. Individual results may vary. Flexibility to Conform with the Anatomy BARD ® and FLAIR ® are trademarks of C. R. Bard, Inc. 12. Semin Intervent Radiol. 2011;28(1): GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. 11. The Gore REVISE Clinical Study Courtesy of William DaVanzo, MD

Durability to Last Under Mechanical Strain No reported fractures in the 24-month study period in Gore REVISE Clinical Study. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. These studies are representative cases. Individual results may vary.

Durability to Last Under Mechanical Strain No reported fractures in the 24-month study period in Gore REVISE Clinical Study. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. These studies are representative cases. Individual results may vary.

The Gore REVISE Clinical Study The Gore REVISE Clinical Study was a multicenter, randomized-controlled trial evaluating the safety and effectiveness of the GORE ® VIABAHN ® Endoprosthesis in treating stenosis or thrombotic occlusions of a synthetic arteriovenous (AV) access graft at the venous anastomosis. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. GORE ® VIABAHN ® Endoprosthesis versus Angioplasty

Definitions Target Lesion Primary Patency: The time interval of uninterrupted patency from initial study treatment to the next access thrombosis or intervention performed on the target lesion. Circuit Primary Patency: The time interval from initial study treatment to the next access thrombosis or intervention performed within the vascular access circuit. Access Secondary Patency: The time interval from initial study treatment to abandonment of the vascular access circuit. The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

The Gore REVISE Clinical Study Primary Safety Endpoint Freedom from major device, procedure, and treatment site-related adverse events through 30 days post-procedure (was met p < ). GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Primary Effectiveness Endpoint: The GORE ® VIABAHN ® Device group demonstrated statistical superiority over the PTA group in target lesion primary patency as determined by Kaplan-Meier estimates (p = 0.008). The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Greater patency for both thrombotic and non-thrombotic patients The Gore REVISE Clinical Study Despite the reduced patency outcomes for thrombotic patients, no statistical difference was detected in terms of treatment effect of the GORE ® VIABAHN ® Device relative to PTA (p = 0.792). GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Exceeded KDOQI Expectations in Thrombosis Patients KDOQI Guideline 6.8.2: Circuit Primary Patency > 40% at three months The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. Stents / stent-grafts were necessary to produce the secondary patency outcomes of the PTA group.

Mean Cumulative Interventions per Subject over 24 Months The Gore REVISE Clinical Study Reduced interventions per subject GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Prior interventions did not affect outcomes for GORE ® VIABAHN ® Device group, but did for the PTA group. The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Flaring not necessary for quality outcomes The Gore REVISE Clinical Study GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

Comparison of the Gore REVISE Clinical Study to the Bard FLAIR Pivotal Study Gore REVISE Clinical Study included, but the Bard FLAIR Pivotal Study excluded: Stenosis > 7 cm from anastomosis Thrombosis patients (43% of subjects) Crossing the elbow and angles > 90 o Conclusions from comparisons of different clinical studies should be made with caution as the poolability of the different subject cohorts was not determined statistically GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc.

References 1. Yoon YC, Shin BS, Ahn M, Park MH, Ohm JY, Kim HJ. Comparison of a nitinol stent versus balloon angioplasty for treatment of a dysfunctional arteriovenous graft. Journal of the Korean Society of Radiology 2012;66(6): Vogel PM, Parise C. SMART stent for salvage of hemodialysis access grafts. Journal of Vascular & Interventional Radiology 2004;15(10): Vogel PM, Parise C. Comparison of SMART stent placement for arteriovenous graft salvage versus successful graft PTA. Journal of Vascular & Interventional Radiology 2005;16(12): Liang HL, Pan HB, Lin YH, et al. Metallic stent placement in hemodialysis graft patients after insufficient balloon dilation. Korean Journal of Radiology 2006;7(2): Maya ID, Allon M. Outcomes of thrombosed arteriovenous grafts: comparison of stents vs angioplasty. Kidney International 2006;69(5): Chan MR, Bedi RJ, et al. Stent placement versus angioplasty improves patency of arteriovenous grafts and blood flow of arteriovenous fistulae. Clinical Journal of the American Society of Nephrology 2008;3(3): Hatakeyama S, Toikawa T, Okamoto A, et al. Efficacy of SMART stent placement for salvage antioplasty in hemodialysis patients with recurrent vascular access stenosis. International Journal of Nephrology 2011;2011: Kim CY, Tandberg DJ, Rosenberg MD, Miller MJ, Suhocki PV, Smith TP. Outcomes of prosthetic hemodialysis grafts after deployment of bare metal versus covered stents at the venous anastomosis. Cardiovascular & Interventional Radiology 2012;35(4): Vesely TM, Siegel JB. Use of the peripheral cutting balloon to treat hemodialysis-related stenoses. Journal of Vascular & Interventional Radiology 2005;16(12): Haskal ZJ, Trerotola S, Dolmatch B, et al. Stent graft versus balloon angioplasty for failing dialysis-access grafts. New England Journal of Medicine 2010;362(6): W. L. Gore & Associates, Inc. GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis (REVISE). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine; Published August 15, Updated January 23, Accessed October 8, NLM Identifier: NCT Funaki B, Slaby J. Covered stent compression in dialysis access. Seminars in Interventional Radiology 2011;28(1):

Products listed may not be available in all markets. BARD ® and FLAIR ® are trademarks of C. R. Bard, Inc. GORE ®, VIABAHN ®, and designs are trademarks of W. L. Gore & Associates. © 2014 W. L. Gore & Associates, Inc. AT0713-EN2 NOVEMBER 2014 INTENDED USE / INDICATIONS: The GORE ® VIABAHN ® Endoprosthesis is indicated for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery de novo and restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 7.5 mm, in superficial femoral artery in-stent restenotic lesions up to 270 mm in length with reference vessel diameters ranging from 4.0 – 6.5 mm, and in iliac artery lesions up to 80 mm in length with reference vessel diameters ranging from 4.0 – 12 mm. The GORE ® VIABAHN ® Endoprosthesis is also indicated for the treatment of stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access grafts. Refer to Instructions for Use at goremedical.com for a complete description of all contraindications, warnings, precautions and adverse events.